An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma

Running, not enrolling · Not applicable

Conditions studied: Pancreas Cancer, Gastrointestinal Adenocarcinoma

In brief

The purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately as CT scans that involve contrast material (also called contrast-enhanced CT scans). All participants in this study will have pancreatic ductal adenocarcinoma (PDAC) that has spread (metastasized) to the liver, and all participants will be scheduled for a routine CT scan that will measure their cancer.

Key facts

Study ID

NCT04837833

Run by

Memorial Sloan Kettering Cancer Center

People needed

19

Starts

2021-04-06

Expected to finish

2027-04-06

Last updated by the study team

2026-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients, 18 years of age or older
• Confirmed diagnosis of PDAC or GI tract adenocarcinoma metastatic to liver
• Scheduled for imaging with contrast enhanced CT

You may not qualify if…

• Inability to tolerate intravenous contrast medium
• All liver metastases ≤ 10 mm in maximal diameter on the contrast enhanced CT used for comparison to the planned research ultrasound
• Multiple confluent liver metastases or tumor burden > 50% of the liver as estimated by a radiologist

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.